|本期目录/Table of Contents|

[1]郭艳,鲍莉,纪猛,等.多能干细胞治疗视网膜退行性疾病：从实验室到临床转化的现状与挑战[J].浙江理工大学学报,2024,51-52(自科一):130-144.
　GUO Yan,BAO Li,JI Meng,et al.Pluripotent stem cells in the treatment of retinal degenerative diseases:Current situation and challenges from bench to bedside[J].Journal of Zhejiang Sci-Tech University,2024,51-52(自科一):130-144.
点击复制

多能干细胞治疗视网膜退行性疾病：从实验室到临床转化的现状与挑战()
分享到：

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
第51-52卷
期数:
2024年自科第一期
页码:
130-144
栏目:
出版日期:
2024-01-11

文章信息/Info

Title:
Pluripotent stem cells in the treatment of retinal degenerative diseases:Current situation and challenges from bench to bedside
文章编号:
1673-3851 (2024) 01-0130-15
作者:
郭艳; 鲍莉; 纪猛; 吴月红
1.浙江理工大学生命科学与医药学院，杭州 310018；2.浙江泉生生物工程有限公司，杭州 310018
Author(s):
GUO Yan; BAO Li; JI Meng; WU Yuehong
1.College of Life Science and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China;2.Asia Stem Cell Therapeutics Co., Ltd., Hangzhou 310018, China
关键词:
人多能干细胞; 视网膜色素上皮细胞; 年龄相关性黄斑变性; Stargardt病; 色素性视网膜炎; 细胞治疗
分类号:
Q291
文献标志码:
A
摘要:
视网膜色素上皮细胞（Retinal pigment epithelial cells, RPE）是位于视网膜底部致密的细胞层，其损伤导致年龄相关性黄斑变性（Age related macular degeneration, AMD）、Stargardt病（Stargardt macular dystrophy, STGD）和色素性视网膜炎（Retinitis pigmentosa, RP）等视网膜疾病，RPE移植已成为治疗RPE损伤性疾病的有效方案。来源于人多能干细胞（Human pluripotent stem cells, hPSC）的视网膜色素上皮细胞，具有与人原代RPE相似的功能和容易制备等优点，已成为RPE移植的最主要细胞来源之一。文章对hPSC-RPE治疗视网膜退行性疾病的临床试验进展进行了总结和归纳，并阐述了目前面临的挑战与风险。

参考文献/References:

［ 1 ］ Thomas C J, Mirza R G, Gill M K. Age - related macular degeneration ［ J ］ . The Medical Clinics of North America, 2021, 105(3): 473 - 491.

［2］Lang M, Harris A, Ciulla T A, et al. Vascular dysfunction in retinitis pigmentosa［J］. Acta Ophthalmologica, 2019, 97(7): 660-664.

［3］Heath Jeffery R C, Chen F K. Stargardt disease: Multimodal imaging: A review［J］. Clinical & Experimental Ophthalmology, 2021, 49(5): 498-515.

［4］Yip Henry K. Retinal stem cells and regeneration of vision system［J］. Anatomical Record, 2014, 297(1): 137-160.

［5］Chichagova V, Hallam D, Collin J, et al. Cellular regeneration strategies for macular degeneration: Past, present and future［J］. Eye, 2018, 32(5):946-971.

［6］Rohowetz Landon J, Peter K. Stem cell-derived retinal pigment epithelium cell therapy: Past and future directions［J］. Frontiers in Cell and Developmental Biology, 2023, 11:1098406.

［7］Akiba R, Takahashi M, Baba T, et al. Progress of iPS cell-based transplantation therapy for retinal diseases［J］. Japanese Journal of Ophthalmology, 2023, 67(2):119-128.

［8］Devika B, Davide O, Mitra F, et al. Considerations for developing an autologous induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) replacement therapy ［J］.Cold Spring Harbor Perspectives in Medicine, 2023, 13(8): a041295.

［9］Lakkaraju A, Umapathy A, Tan L X, et al. The cell biology of the retinal pigment epithelium［J］. Progress in Retinal and Eye Research, 2020, 78: 100846.

［10］Lehmann G L, Benedicto I, Philp N J, et al. Plasma membrane protein polarity and trafficking in RPE cells: Past, present and future［J］. Experimental Eye Research_, 2014, 126: 5-15.

undefined

备注/Memo

备注/Memo:
收稿日期：2023-06-18
网络出版日期：2023-11-02
基金项目：企业委托研发项目(21040400-J) 中文基金项目
作者简介：郭艳(1998—)，女，甘肃通渭人，硕士研究生，主要从事多能干细胞方面的研究
通信作者：吴月红，E-mail：wuyuehong2003@163.com
更新日期/Last Update: 2024-01-10